

# Association Analysis of Polymorphisms in Lumican Gene and Systemic Lupus Erythematosus in a Taiwan Chinese Han Population

PEI-CHUN CHANG, YI CHEN, MING-TSONG LAI, HENG-YUAN CHANG, CHUNG-MING HUANG, HSIN-PING LIU, WEI-YONG LIN, CHIH-HO LAI, JIM JINN-CHYUAN SHEU, and FUU-JEN TSAI

**ABSTRACT. Objective.** Lumican (LUM) is predominantly localized in areas of pathological fibrosis. To determine whether polymorphisms in *LUM* gene are associated with development of systemic lupus erythematosus (SLE), we analyzed 2 single-nucleotide polymorphisms (SNP) of *LUM* in a Taiwan Chinese Han population.

**Methods.** Participants included 168 patients with SLE and 192 age-matched controls in whom examinations had excluded SLE. Genotyping of -628 A/- (rs17018757) and c.1567 T/C polymorphisms in *LUM* were carried out in each patient and control using the polymerase chain reaction-restriction fragment-length polymorphism method, and validated by Taqman SNP genotyping assay. Data were correlated with the development of SLE and various clinical symptoms by chi-square analysis.

**Results.** Frequencies of C/C genotype and the C allele at c.1567 T/C were significantly higher in patients than controls. Polymorphism at c.1567 C/T was found to be associated with arthritis and photosensitivity in patients with SLE, which are both connective tissue-related symptoms.

**Conclusion.** The c.1567 T/C polymorphism of *LUM* is related to the development and clinical symptoms of SLE. (J Rheumatol First Release Sep 1 2011; doi:10.3899/jrheum.101310)

*Key Indexing Terms:*

LUMICAN

SINGLE-NUCLEOTIDE POLYMORPHISMS

SYSTEMIC LUPUS ERYTHEMATOSUS  
SMALL LEUCINE-RICH PROTEOGLYCAN

Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disease causing accumulative damage on multiple organs<sup>1,2,3</sup>. Clinical manifestations of SLE include rash, arthritis, nephritis, anemia, thrombocytopenia, serositis, vasculitis, and neuropsychiatric defects<sup>3,4,5,6</sup>. Clinical phenotypes of SLE are highly variable in patients, affecting multiple organs such as skin, joints, lungs, kidneys, hematopoietic organs, and nervous system<sup>3,7,8,9</sup>. It is still unclear why the same disease can affect individuals with highly variable phenotypes and severities. Studies have indicated that genetic, environmental, and hormonal factors

are implicated in the heterogeneity of SLE<sup>1,2,10,11,12</sup>. Besides SLE, some other connective tissue diseases such as systemic sclerosis and rheumatoid arthritis (RA) share common pathogenic features including malfunction of the immune system, inflammation, and fibrosis<sup>7,13</sup>.

Lumican (LUM) is a member of the structurally related small leucine-rich proteoglycan (SLRP) family<sup>14</sup>, which regulates extracellular matrix (ECM) remodeling through coordinately modulating fibrillogenesis and collagen turnover<sup>15,16</sup>. In various connective tissues, fibrotic ECM accumulation, accompanied by alterations of SLRP expres-

*From the Department of Bioinformatics, and Department of Health and Nutrition Biotechnology, Asia University, Taichung; Human Genetic Center, and Department of Internal Medicine, China Medical University Hospital, Taichung; Department of Pathology, Chung Shan Medical University Hospital, Taichung; School of Medicine, Chung Shan Medical University, Taichung; Graduate Institute of Acupuncture Science, Graduate Institute of Integrated Medicine, School of Medicine, School of Chinese Medicine, and School of Post-Baccalaureate Chinese Medicine, China Medical University, Taichung; and Department of Pharmacy, Yongkang Veterans Hospital, Tainan, Taiwan.*

*Supported by medical science research grants from China Medical University Hospital (DMR 97-062), and the Asia University-China Medical University Collaboration Fund (CMU98-asia-02).*

*P-C. Chang, PhD, Department of Bioinformatics, Asia University; Y. Chen, PhD, Human Genetic Center, China Medical University Hospital; M-T. Lai, MD, PhD, Department of Pathology, School of Medicine, Chung Shan Medical University; H-Y. Chang, PhD, Human Genetic Center, China Medical University Hospital, Department of*

*Pharmacy, Yongkang Veterans Hospital; C-M. Huang, MD, Department of Internal Medicine, China Medical University Hospital; H-P. Liu, PhD, Graduate Institute of Acupuncture Science, China Medical University; W-Y. Lin, PhD, Human Genetic Center, China Medical University Hospital, Graduate Institute of Integrated Medicine, China Medical University; C-H. Lai, PhD, School of Medicine, China Medical University; J-J-C. Sheu, PhD, Department of Health and Nutrition Biotechnology, Asia University, Human Genetic Center, China Medical University Hospital, School of Chinese Medicine, China Medical University; F-J. Tsai, MD, PhD, Human Genetic Center, China Medical University Hospital, and School of Post-Baccalaureate Chinese Medicine, China Medical University.*

*P-C. Chang, Y. Chen, and M-T. Lai contributed equally to this study.*

*Address correspondence to Dr. F-J. Tsai, Human Genetic Center, 11F Fu-Jiang Building, China Medical University Hospital, 2 Yuh-Der Road, Taichung City 40447, Taiwan. E-mail: d0704@mail.cmuh.org.tw; or Dr. J.J.C. Sheu, jimsheu@mail.cmu.edu.tw*

*Accepted for publication June 15, 2011.*

Personal non-commercial use only. The Journal of Rheumatology Copyright © 2011. All rights reserved.

sion profiles, is often linked to tissue destruction and pathogenic fibrosis<sup>17,18,19,20</sup>.

Histochemically, LUM is found as the primary keratan sulfate proteoglycan in the corneal stroma, and also in the ECM of skin, muscle, and cartilage<sup>21,22,23</sup>. Studies have indicated that LUM is prominently expressed in areas of pathological fibrosis<sup>24,25,26</sup>, and participates in cell signaling by regulating the activity of transforming growth factor- $\beta$  (TGF- $\beta$ )<sup>25,27</sup>. As an immune modulator, decreased level of TGF- $\beta$  was coupled to the onset and severity of SLE<sup>28</sup>. In addition, TGF- $\beta$  activation following cellular inflammatory response also causes an increase of ECM components, which in turn leads to fibrosis in various inflammatory diseases such as RA and myocarditis<sup>29,30,31</sup>. Based on these findings, we propose that LUM may play a role in the development of SLE, which exhibits symptoms of both inflammation and fibrosis.

The human *LUM* gene spreads over 7.5 kb of genomic DNA and is located on chromosome 12q22<sup>32</sup>. This gene consists of 3 exons separated by introns of 2.2 kb and 3.5 kb length. The shorter 5'-intron resides 21 bp upstream of the translation initiation codon, and the 3'-intron 152 bp upstream of the translation termination codon<sup>33</sup>. By sequencing polymerase chain reaction (PCR)-amplified genomic DNA, Lin, *et al* found that 2 SNP in the *LUM* gene, -628 A/- and c.1567 C/T, were associated with the development of high myopia in a Taiwan Chinese Han population<sup>34</sup>. They further demonstrated that the c.1567 C/T SNP may influence the expression of *LUM*<sup>34</sup>. Since myopia is also a connective tissue disease, we decided to evaluate whether these polymorphisms are associated with SLE in a Taiwan Chinese Han population with or without this disease.

## MATERIALS AND METHODS

**Patients and sample collection.** A total of 168 patients with SLE and 192 healthy age-matched controls were recruited from the China Medical University Hospital in Taiwan. The clinical features of the selected patients met the criteria for SLE of the American Rheumatism Association<sup>35</sup>. Controls were selected from individuals undergoing regular health check-ups at the same hospital and certified as healthy based on those examinations. Blood samples were collected by venipuncture for blood cell isolation and genomic DNA preparation. This study was approved by the Institutional Review Board of the China Medical University Hospital prior to patient enrollment. All participants provided informed consent.

**Genotyping.** Genomic DNA was prepared from peripheral blood leukocytes according to standard protocols (DNA extractor WB kit; Wako Pure Chemical Industries, Osaka, Japan). PCR procedures for *LUM* gene polymorphisms were performed in a 50  $\mu$ l reaction mixture containing 50 ng genomic DNA, 2 ~ 6 pmol of each primer, 1 $\times$  Taq polymerase buffer (1.5 mM MgCl<sub>2</sub>), 0.25 mM dNTP, and 0.25 U of Taq DNA polymerase (AmpliTaq; Applied Biosystems, Carlsbad, CA, USA). PCR products were amplified with an initial denaturation at 95°C for 5 min, followed by a 25-cycle program (95°C for 30 s, 60°C or 57°C for 30 s, and 72°C for 1 min). The primers, PCR conditions, and restriction enzyme cutting sites used to determine polymorphisms in *LUM* gene are listed in Table 1. Restriction enzyme HpyCH4V and AluI were used for the PCR products of -628 and c.1567, respectively. PCR products were digested by the restriction enzymes at 37°C for 4 h and overnight. Gel electrophoresis of the digested

DNA products confirmed that the cutting was completed within 4 h, and the prolonged digestion time did not alter the results. Sequence detections were performed in an ABI Prism 3100 Genetic Analyzer (Applied Biosystems). DNA fragments were separated and analyzed using Prism GeneMapper 3.0 (Applied Biosystems). Genotyping results from the PCR-restriction fragment-length polymorphism (RFLP) method were further validated using the Taqman SNP genotyping assay system (Applied Biosystems). Probes for the -628 and c.1567 polymorphism of *LUM* were custom-designed using the sequences of their flanking regions. PCR amplification conditions consisted of initial denaturation at 95°C for 5 min, followed by 40 cycles of 95°C for 15 s, and 60°C for 60 s. Genetic variations were detected by reading the fluorescence signals of PCR products. A positive signal indicates a perfect match between the probe and the tested DNA, thus identifying the allele types.

**Statistical analysis.** The genotype and allelic frequency distributions of the *LUM* polymorphisms in patients with SLE and controls were analyzed by the chi-square method using SPSS (version 10.0; SPSS Inc., Chicago, IL, USA).  $P < 0.05$  was considered statistically significant. Odds ratios were calculated for both genotype and allelic frequencies with a 95% CI. Genotype data were checked for deviation from Hardy-Weinberg equilibrium using the PLINK program<sup>36</sup>.

## RESULTS


**Allelic and genotype frequencies of *LUM* polymorphisms.** Using the PCR-RFLP method, we determined the presence of -628 A/- (rs17018757) and c.1567 C/T polymorphisms of *LUM* gene. A representative gel image of the enzyme digestion product of the PCR products for both SNP is shown in Figure 1, panel A. The PCR products with deletion at -628 were digested by the enzyme HpyCH4V and generated 2 fragments. The PCR products with T allele at c.1567 were digested by APuI and generated 4 fragments (Table 1). We further validated the genotyping results from PCR-RFLP by Taqman SNP genotyping assays. The fluorescence signal plots are shown in Figure 1, panels B and C, for -628 and c.1567, respectively.

The genotyping data revealed significant differences in both the allelic and genotype distributions of the c.1567 SNP between patients with SLE and healthy controls. The genotype and allele frequencies of the 2 polymorphisms are summarized in Table 2. Both the C/C and C/T genotypes were observed more frequently in patients with SLE compared to controls. A significant difference in the distribution of the c.1567 C/T genotype was found between patients with SLE and controls ( $p = 0.011$ ; OR 2.53, 95% CI 1.24–5.18; Table 2). In addition, allelic frequencies of the c.1567 C/T polymorphism also varied significantly between patients with SLE and controls ( $p = 0.0029$ ; OR 1.60, 95% CI 1.17–2.20; Table 2). This result indicated that the C allele at c.1567 may be a predisposing risk factor for development of SLE. However, the  $p$  values from chi-square tests indicated no significant differences between patients and controls in either allelic or genotype frequencies of the -628 A/- polymorphism (Table 2).  $P$  values for Hardy-Weinberg equilibrium for both -628 and c.1567 SNP were all  $> 0.05$  in patients and controls (Table 2), indicating that the genotype distributions respect the Hardy-Weinberg equilibrium.

*Table 1.* Primers and PCR conditions used to determine *LUM* gene polymorphisms. F and R indicate forward and reverse primers, respectively. Numbering of *LUM* gene according to Genebank accession no. NM\_002345.3 and promoter numbering Genebank accession no. AF239660. The first base of the first exon is numbered +1.

Set	Primer and PCR Condition	PCR Product, bp	Restriction Enzyme
-628 A/- (rs17018757)	F 5' -GAA TGC TCT CCC CAA GTA AGG-3' R 5' -CAG GAA AAC GCA AAT GAA CAG A-3' 95°C × 5 min, 95°C × 30 s, and 60°C × 30 s	118 + 199	HpyCH4V
c.1567 C/T	F 5' -GCA TGG AAA TCA GCC AAG TT-3' R 5' -AAC ACA GTG ATG CCA TTT GC-3' 95°C × 5 min, 95°C × 30 s, and 57°C × 30 s	52 + 131 + 122 + 41	AluI

PCR: polymerase chain reaction.



*Figure 1.* A. Restriction enzyme digestion of the polymerase chain reaction products for *LUM* gene polymorphisms. The last lane is the DNA size marker. From the bottom: 100 bp, 200 bp, 300 bp, 400 bp, 500 bp, etc. Left to right, the lanes represent -/-, A/A, and A/- genotypes of -628; C/T, T/T, and C/C genotypes of c.1567, respectively. B and C. Fluorescence signal plots from Taqman genotyping assays for -628 A/- (rs17018757) and c.1567 C/T polymorphisms.

*Linkage of c.1567 polymorphism of LUM to clinical symptoms in patients with SLE.* The association between 11 clinical features and allele distributions in patients with SLE was analyzed, and the results are summarized in Table 3. Comparing SLE patients with and without the symptoms, the c.1567 polymorphism of *LUM* is associated with the development of arthritis and photosensitivity ( $p = 0.0064$  and  $0.030$ , respectively; Table 3). Since *LUM* is involved in the regulation of ECM structure in various connective tissues including cartilage and skin, the c.1567 polymorphism may be capable of modifying the expression of the *LUM* gene<sup>34</sup>. Therefore, it is not surprising that the connective tissue-related symptoms such as arthritis and photosensitivity

exhibited high odds ratios in patients with the C allele at c.1567 of *LUM*.

## DISCUSSION

Our discovery that the *LUM* gene represents a novel genetic risk factor for development of SLE provides new perspectives in the study of molecular mechanisms underlying the pathogenesis and progression of SLE. SLE is a multiorgan disease whose pathogenesis is attributed to genetic and environmental factors and immune system abnormalities<sup>37</sup>. Recent advances in genome-wide association studies have identified more than 30 genes associated with SLE, most involved in the immune response-related pathways<sup>38</sup>.

Table 2. Genotype and allele frequencies of *LUM* polymorphisms in Taiwan Chinese Han patients with SLE and controls.

Polymorphisms	Genotype	Cases (%)	HWE	Controls (%)	HWE	p <sup>†</sup>	OR (95% CI)
c.-628 (rs17018757)	-/-	11 (6.6)	0.32	10 (5.2)	0.83	0.237	1.50 (0.61–3.70)
	A/-	73 (44.0)		70 (36.5)			1.42 (0.92–2.25)
	A/A	82 (49.4)		112 (58.3)			1 (reference)
	—	95 (28.6)		90 (23.4)			0.11
c.1567	A	237 (71.4)	0.53	294 (76.6)	0.86	0.011*	1 (reference)
	C/C	24 (14.3)		15 (8.0)			2.53 (1.24–5.18)
	C/T	84 (50.0)		78 (41.5)			1.71 (1.09–2.67)
	T/T	60 (35.7)		95 (50.5)			1 (reference)
	C	132 (39.3)		108 (28.7)			0.0029*
	T	204 (60.7)	268 (71.3)	1 (reference)			

<sup>†</sup> Genotype and allele frequencies were compared between patients with SLE and controls. p values are calculated by chi-square test without correction for multiple tests. \* Indicates statistical significance. HWE: Hardy-Weinberg equilibrium.

Table 3. Association study of c.1567 C/T of *LUM* in patients with SLE stratified by 11 clinical symptoms.

Phenotypes	Positive (%)	Negative (%)	p <sup>†</sup>	OR (95% CI)
Antinuclear antibody	82 (96.8)	3 (3.7)	0.93	0.92 (0.16–5.17)
Immunologic disorder	74 (77.9)	21 (22.1)	0.95	0.97 (0.46–2.05)
Hematologic disorder	46 (48.4)	49 (51.6)	0.45	1.27 (0.69–2.35)
Central nervous system	10 (10.5)	85 (89.5)	0.15	1.96 (0.77–5.03)
Renal	38 (40.0)	57 (60.0)	0.65	1.15 (0.62–2.15)
Serositis	20 (21.1)	75 (78.9)	0.54	1.26 (0.60–2.63)
Arthritis	44 (46.3)	51 (53.7)	0.0064*	2.38 (1.27–4.46)
Mucosal ulcer	34 (35.4)	62 (64.6)	0.68	0.88 (0.46–1.66)
Photosensitivity	43 (46.7)	49 (53.3)	0.030*	2.05 (1.06–3.94)
Discoid lupus	13 (13.5)	83 (86.5)	0.19	1.75 (0.75–4.08)
Malar rash	48 (50.5)	47 (49.5)	0.068	1.78 (0.95–3.32)

<sup>†</sup> Comparisons between the positive and negative groups by chi-square test of the allele distributions. p values are calculated without correction for multiple tests. \* Indicates statistical significance. Positive: Patients positive for a certain phenotype. Negative: Patients negative for a certain phenotype.

Knowledge of the role of LUM in immune regulation remains limited, and related studies are mostly focused on its regulation in collagen fibril organization, corneal transparency, cell migration, and tissue repair<sup>14,39,40,41</sup>. Nevertheless, one study in 2007 demonstrated a regulatory role of LUM in the innate immune response via the Toll-like receptor (TLR) pathway<sup>42</sup>. Recently, TLR have been shown to be involved in the pathogenesis of SLE through activation of immune cells and upregulation of many disease-related cytokines<sup>43</sup>. The possible roles of LUM in immune regulation need to be further defined.

Correct amounts of SLRP, including LUM, are crucial for the normal function of various ECM-rich tissues such as skin, tendon, muscle, and cornea of the eye. Schaefer, *et al*<sup>44</sup> discovered distinct expression patterns of LUM, decorin, biglycan, and fibromodulin, the 4 members of the SLRP family, in adult human kidney cortex. Their study provided a basis for elucidating specific roles of the individual SLRP members in the pathogenesis of fibrotic kidney diseases<sup>44</sup>.

In common with other connective tissues, cartilage also contains a variety of SLRP, which are a minor component of tissue considering their weight, but on a molar basis may rival the abundance of aggrecan<sup>45</sup>. Along with LUM, other major SLRP all help to maintain the integrity of tissue and modulate its metabolism<sup>45</sup>. LUM is a keratan sulfate-bearing type of SLRP that can bind fibrillar collagens and function in the assembly of collagen networks in connective tissues<sup>46,47</sup>.

In our study, the functional SNP in *LUM* gene that have been previously linked to myopia were also found to be significantly associated with SLE, suggesting that SLE may share similar pathogenic pathways with other connective tissue diseases. Misguided complement activation, which constitutes an essential part of the innate immune system, is the culprit in many connective tissue diseases such as macular degeneration, SLE, multiple sclerosis, osteoarthritis, and RA<sup>48,49,50</sup>. Several SLRP were found to interact with complement factors and activate the classical pathway of complement activation<sup>51</sup>. Therefore, LUM may also be involved



in such processes as we found, that the c.1567 C/T polymorphism of LUM is associated with the development of SLE disease, as well as clinical symptoms manifested in connective tissues such as arthritis and photosensitivity. Moreover, the relationship with those clinical symptoms is also consistent with the fact that LUM is crucial for maintenance of normal functioning of skin tissue<sup>47,52</sup>. Therefore, genetic variations of LUM may act as a common pathogenic linkage between SLE and other connective tissue diseases. The pathologic effects of the genetic variations on ECM architecture may represent an indicator of LUM's activity within a variety of tissues affected by SLE, and aid in elucidating its cellular and molecular functions.

## ACKNOWLEDGMENT

We appreciate the kind assistance of Yi-Ting Hisao and Carmen Chan at China Medical University Hospital, Taiwan.

## REFERENCES

- Kotzin BL. Systemic lupus erythematosus. *Cell* 1996;85:303-6.
- Sawalha AH, Kaufman KM, Kelly JA, Adler AJ, Aberle T, Kilpatrick J, et al. Genetic association of interleukin-21 polymorphisms with systemic lupus erythematosus. *Ann Rheum Dis* 2008;67:458-61.
- Swigris JJ, Fischer A, Gillis J, Meehan RT, Brown KK. Pulmonary and thrombotic manifestations of systemic lupus erythematosus. *Chest* 2008;133:271-80.
- Manson JJ, Rahman A. Systemic lupus erythematosus. *Orphanet J Rare Dis* 2006;1:6.
- Guillevin L. Vasculopathy and pulmonary arterial hypertension. *Rheumatology* 2009;48 Suppl 3:iii54-7.
- Bertsias GK, Boumpas DT. Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. *Nat Rev Rheumatol* 2010;6:358-67.
- Tyndall A, Matucci-Cerinic M, Muller-Ladner U. Future targets in the management of systemic sclerosis. *Rheumatology* 2009;48 Suppl 3:iii49-53.
- Bagavant H, Fu SM. Pathogenesis of kidney disease in systemic lupus erythematosus. *Curr Opin Rheumatol* 2009;21:489-94.
- Crispin JC, Liossis SN, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. *Trends Mol Med* 2010;16:47-57.
- Sarzi-Puttini P, Atzeni F, Iaccarino L, Doria A. Environment and systemic lupus erythematosus: an overview. *Autoimmunity* 2005;38:465-72.
- Sekigawa I, Fujishiro M, Yamaguchi A, Kawasaki M, Inui A, Nozawa K, et al. A new hypothesis of the possible mechanisms of gender differences in systemic lupus erythematosus. *Clin Exp Rheumatol* 2010;28:419-23.
- Rood MJ, van der Velde EA, ten Cate R, Breedveld FC, Huizinga TW. Female sex hormones at the onset of systemic lupus erythematosus affect survival. *Br J Rheumatol* 1998;37:1008-10.
- Manson JJ, Isenberg DA. The pathogenesis of systemic lupus erythematosus. *Neth J Med* 2003;61:343-6.
- Nikitovic D, Katonis P, Tsatsakis A, Karamanos NK, Tzanakakis GN. Lumican, a small leucine-rich proteoglycan. *IUBMB Life* 2008;60:818-23.
- Kalamajski S, Oldberg A. The role of small leucine-rich proteoglycans in collagen fibrillogenesis. *Matrix Biol* 2010; 29:248-53.
- Matheson S, Larjava H, Hakkinen L. Distinctive localization and function for lumican, fibromodulin and decorin to regulate collagen fibril organization in periodontal tissues. *J Periodontol Res* 2005;40:312-24.
- Funderburgh JL, Mann MM, Funderburgh ML. Keratocyte phenotype mediates proteoglycan structure: a role for fibroblasts in corneal fibrosis. *J Biol Chem* 2003;278:45629-37.
- Alowami S, Troup S, Al-Haddad S, Kirkpatrick I, Watson PH. Mammographic density is related to stroma and stromal proteoglycan expression. *Breast Cancer Res* 2003;5:R129-35.
- Khan T, Muise ES, Iyengar P, Wang ZV, Chandalia M, Abate N, et al. Metabolic dysregulation and adipose tissue fibrosis: role of collagen VI. *Mol Cell Biol* 2009;29:1575-91.
- Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. *Mucosal Immunol* 2009;2:103-21.
- Iozzo RV, Murdoch AD. Proteoglycans of the extracellular environment: clues from the gene and protein side offer novel perspectives in molecular diversity and function. *FASEB J* 1996;10:598-614.
- Hocking AM, Shinomura T, McQuillan DJ. Leucine-rich repeat glycoproteins of the extracellular matrix. *Matrix Biol* 1998;17:1-19.
- Iozzo RV. The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins. *J Biol Chem* 1999;274:18843-6.
- Onda M, Ishiwata T, Kawahara K, Wang R, Naito Z, Sugisaki Y. Expression of lumican in thickened intima and smooth muscle cells in human coronary atherosclerosis. *Exp Mol Pathol* 2002;72:142-9.
- Naito Z. Role of the small leucine-rich proteoglycan (SLRP) family in pathological lesions and cancer cell growth. *J Nippon Med Sch* 2005;72:137-45.
- Ping Lu Y, Ishiwata T, Asano G. Lumican expression in alpha cells of islets in pancreas and pancreatic cancer cells. *J Pathol* 2002;196:324-30.
- Nikitovic D, Berdiaki A, Zafiroopoulos A, Katonis P, Tsatsakis A, Karamanos NK, et al. Lumican expression is positively correlated with the differentiation and negatively with the growth of human osteosarcoma cells. *FEBS J* 2008;275:350-61.
- Ohtsuka K, Gray JD, Stimmler MM, Horwitz DA. The relationship between defects in lymphocyte production of transforming growth factor-beta 1 in systemic lupus erythematosus and disease activity or severity. *Lupus* 1999;8:90-4.
- Branton MH, Kopp JB. TGF-beta and fibrosis. *Microbes Infect* 1999;1:1349-65.
- Salvador G, Sanmarti R, Gil-Torregrosa B, Garcia-Peiro A, Rodriguez-Cros JR, Canete JD. Synovial vascular patterns and angiogenic factors expression in synovial tissue and serum of patients with rheumatoid arthritis. *Rheumatology* 2006;45:966-71.
- Rosenkranz S, Flesch M, Amann K, Haeuseler C, Kilter H, Seeland U, et al. Alterations of beta-adrenergic signaling and cardiac hypertrophy in transgenic mice overexpressing TGF-beta(1). *Am J Physiol Heart Circ Physiol* 2002;283:H1253-62.
- Chakravarti S, Stallings RL, SundarRaj N, Cornuet PK, Hassell JR. Primary structure of human lumican (keratan sulfate proteoglycan) and localization of the gene (LUM) to chromosome 12q21.3-q22. *Genomics* 1995;27:481-8.
- Grover J, Chen XN, Korenberg JR, Roughley PJ. The human lumican gene. Organization, chromosomal location, and expression in articular cartilage. *J Biol Chem* 1995;270:21942-9.
- Lin HJ, Kung YJ, Lin YJ, Sheu JJ, Chen BH, Lan YC, et al. Association of the lumican gene functional 3'-UTR polymorphism with high myopia. *Invest Ophthalmol Vis Sci* 2010;51:96-102.
- Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982;25:1271-7.
- Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet*

- 2007;81:559-75.
37. Gualtierotti R, Biggioggero M, Penatti AE, Meroni PL. Updating on the pathogenesis of systemic lupus erythematosus. *Autoimmun Rev* 2010;10:3-7.
  38. Deng Y, Tsao BP. Genetic susceptibility to systemic lupus erythematosus in the genomic era. *Nat Rev Rheumatol* 2010; 6:683-92.
  39. Ishiwata T, Cho K, Kawahara K, Yamamoto T, Fujiwara Y, Uchida E, et al. Role of lumican in cancer cells and adjacent stromal tissues in human pancreatic cancer. *Oncol Rep* 2007;18:537-43.
  40. Zeltz C, Brezillon S, Perreau C, Ramont L, Maquart FX, Wegrowski Y. Lumcorin: a leucine-rich repeat 9-derived peptide from human lumican inhibiting melanoma cell migration. *FEBS Lett* 2009;583:3027-32.
  41. Dunlevy JR, Rada JA. Interaction of lumican with aggrecan in the aging human sclera. *Invest Ophthalmol Vis Sci* 2004;45:3849-56.
  42. Wu F, Vij N, Roberts L, Lopez-Briones S, Joyce S, Chakravarti S. A novel role of the lumican core protein in bacterial lipopolysaccharide-induced innate immune response. *J Biol Chem* 2007;282:26409-17.
  43. Richez C, Blanco P, Rifkin I, Moreau JF, Schaeffer T. Role for toll-like receptors in autoimmune disease: The example of systemic lupus erythematosus. *Joint Bone Spine* 2011;78:124-30.
  44. Schaefer L, Grone HJ, Raslik I, Robenek H, Ugorcakova J, Budny S, et al. Small proteoglycans of normal adult human kidney: distinct expression patterns of decorin, biglycan, fibromodulin, and lumican. *Kidney Int* 2000;58:1557-68.
  45. Roughley PJ. The structure and function of cartilage proteoglycans. *Eur Cell Mater* 2006;12:92-101.
  46. Svensson L, Narlid I, Oldberg A. Fibromodulin and lumican bind to the same region on collagen type I fibrils. *FEBS Lett* 2000;470:178-82.
  47. Chakravarti S, Magnuson T, Lass JH, Jepsen KJ, LaMantia C, Carroll H. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. *J Cell Biol* 1998;141:1277-86.
  48. Morgan BP, Walport MJ. Complement deficiency and disease. *Immunol Today* 1991;12:301-6.
  49. Sofat N. Analysing the role of endogenous matrix molecules in the development of osteoarthritis. *Int J Exp Pathol* 2009;90:463-79.
  50. Sjoberg AP, Trouw LA, Blom AM. Complement activation and inhibition: a delicate balance. *Trends Immunol* 2009;30:83-90.
  51. Sjoberg AP, Manderson GA, Morgelin M, Day AJ, Heinegard D, Blom AM. Short leucine-rich glycoproteins of the extracellular matrix display diverse patterns of complement interaction and activation. *Mol Immunol* 2009;46:830-9.
  52. Chakravarti S. Functions of lumican and fibromodulin: lessons from knockout mice. *Glycoconj J* 2002;19:287-93.